DigestRedComo funciona
Red
/
Empresas
Ve
No verificado

Verastem Oncology

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

66 Comunicados de prensa

Ver todos los comunicados de prensa
30/04/2026
Verastem Oncology Launches HCP and Patient Reimagine Campaign to Increase Awareness of AVMAPKI® FAKZYNJA® CO-PACK for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
23/04/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Verastem Oncology to Report First Quarter 2026 Financial Results on May 7, 2026
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
10/04/2026
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Ir de compras
Medicina - Varios
Farmacéutica
Biotecnología
Verastem Oncology Announces Two-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer at the SGO 2026 Annual Meeting on Women’s Cancers
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
02/04/2026
Oncología
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
17/03/2026
Eventos
Industria
Oncología
Salud
Biotecnología
Medicina - Varios
Farmacéutica
Verastem Oncology Announces Late Breaking and Regular Abstracts Accepted for Presentation at the AACR Annual Meeting 2026
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
17/03/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Eventos
Industria
Verastem Oncology Announces Abstracts Accepted for Presentation on AVMAPKI™ FAKZYNJA™ (avutometinib capsules; defactinib tablets) Combination Therapy at the Society of Gynecologic Oncology 2026 Annual Meeting on Women’s Cancers
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
04/03/2026
Web y redes sociales
Telefonía
Mercado de valores
Eventos
Oncología
Salud
Higiene alimentaria
Sanidad
Medicina - Varios
Farmacéutica
Biotecnología
Verastem Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Business Updates
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
18/02/2026
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
Verastem Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
04/02/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Eventos
Mercado de valores
Verastem Oncology Provides Preliminary Fourth Quarter and 2025 Revenue and Business Updates and Outlines 2026 Strategic Priorities for Novel Portfolio Targeting RAS/MAPK Pathway-Driven Cancers
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0
12/01/2026
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Oncología
Mercado de valores
Finanzas
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fuente
Verastem Oncology
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0